PDS Biotechnology (PDSB) announced that it has entered into a securities purchase agreement for the purchase and sale of 5.8M shares of common stock, or pre-funded warrants in lieu thereof, at a purchase price of 91c per share and accompanying warrants to purchase up to an aggregate of 5.8M shares of its common stock in a registered direct offering. The warrants will have an exercise price of $1.00 per share, will be exercisable beginning six months after issuance and will expire five years from the initial exercise date. Craig-Hallum is acting as the exclusive placement agent for the offering.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PDSB:
- PDS Biotechnology Announces Positive Data at Cancer Meeting
- PDS Biotechnology announces data on activity of PDS0101, PDS01ADC
- PDSB Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- PDS Biotechnology Seeks FDA Meeting for PDS0101 Approval
- PDS Biotechnology to seek expedited approval pathway for PDS0101